Fact-checked by Grok 2 weeks ago

Virbac

Virbac is a French animal health company founded in 1968 by veterinarian Pierre-Richard Dick in Nice, specializing in the research, development, production, and distribution of pharmaceuticals, vaccines, diagnostic tools, and other solutions for companion and farm animals. The company operates as an independent entity dedicated exclusively to animal health, with a mission to innovate and deliver products and services that diagnose, prevent, and treat animal diseases while improving the quality of life for animals. Virbac's portfolio focuses primarily on companion animals, which account for 62% of its sales, including dental care products, medications, and supplements for dogs, cats, and other pets, alongside solutions for farm animals comprising 38% of revenue, such as vaccines and treatments for livestock. Headquartered in Carros near Nice, France, Virbac maintains a global presence in over 100 countries and ranks as the sixth-largest veterinary drug manufacturer worldwide. In 2024, the company reported sales of €1,397 million, reflecting a growth of 7.5% at constant exchange rates and scope compared to the previous year.

Overview

Founding and Headquarters

Virbac was founded in 1968 by Pierre-Richard Dick, a who graduated from the Maisons-Alfort veterinary school in 1961 and later trained in at the . Established as Virbac, the company began as a modest biological research center operating out of a three-room apartment in , , with its name derived from "virology" and "bacteriology" to reflect Dick's expertise. At inception, Virbac concentrated solely on animal health research, without any commercial production, driven by Dick's vision to address veterinary needs through scientific innovation. Over its early years, Virbac evolved from a local research outfit into a dedicated health company, maintaining a strong emphasis on independence and veterinary expertise to ensure focused development of solutions for animal diseases. This foundational commitment to autonomy allowed the company to prioritize long-term research goals over short-term commercial pressures, setting the stage for its growth as an exclusively health-oriented entity. Virbac's headquarters are located in Carros, near , , where construction of the central facility began in 1973 to support expanding research, production, and storage needs. Situated at 13e rue LID - BP 27, 06511 Carros, this site serves as the primary hub for strategic and oversight.

Mission and Core Focus

Virbac is an independent pharmaceutical company exclusively dedicated to animal health, with a purpose centered on advancing the health of animals in partnership with s, farmers, and pet owners to foster better lives for all. Founded by a to develop innovative solutions for those who care for animals daily, the company emphasizes improving animal well-being through comprehensive health strategies that integrate prevention, treatment, and care practices. This mission reflects a to supporting veterinary professionals by providing accessible tools and knowledge that enhance everyday animal care. The core focus of Virbac encompasses companion animals such as , , and ferrets, as well as and species, addressing key challenges including zoonotic diseases, , and sustainable production. By prioritizing an integrated approach to animal health, Virbac aims to prevent diseases and promote good husbandry practices across these sectors, ensuring the health of animals contributes to broader human and environmental benefits. Virbac's operations are guided by core values including entrepreneurial spirit, innovation, engagement, customer-driven orientation, attention to people, and , which underpin its emphasis on advancing preventive care, therapeutics, and diagnostics in . The company integrates and ethical practices into its strategy, focusing on respectful treatments that preserve physical integrity, , and long-term ecological balance while combating issues like antibiotic .

History

Early Development (1968–1980s)

In the 1970s, Virbac transitioned from a pure entity to one incorporating and capabilities, establishing a dedicated laboratory in the mid-decade to advance its product development in animal health. This period also marked the company's initial international expansion within , beginning with distribution partnerships in the countries and to broaden access to its veterinary solutions. These developments occurred amid evolving societal views on , influenced by France's 1976 law recognizing domestic animals as sentient beings and the 1978 Universal Declaration of Animal Rights proclaimed at , which underscored ethical considerations in animal care that aligned with Virbac's growing focus on compassionate veterinary innovations. By 1973, Virbac constructed its headquarters in Carros, near , , incorporating production and storage facilities that signified a shift from research-only operations to commercial . In 1977, the company introduced France's first veterinary for use in dogs, , and , addressing key needs in and . Earlier in the decade, Virbac had launched its inaugural for dogs, an early in parasite control for pets. The 1980s brought significant milestones in vaccine technology and market presence. In 1982, Virbac developed the world's first homologous against and established its initial foreign subsidiary in , solidifying its European footprint. This was followed in 1985 by the introduction of prolonged-release boluses for treatment in ruminants, enhancing sustained efficacy in care. By 1988, the company achieved another breakthrough with the launch of the first genetically engineered against feline , demonstrating its commitment to cutting-edge biological solutions. Overall, this era represented Virbac's foundational growth, evolving from a research center into a producer with an emerging subsidiary network in , driven by innovations that addressed pressing veterinary challenges in both companion animals and .

Expansion and Key Milestones (1990s–Present)

In the , Virbac advanced its product innovation while beginning broader international expansion. In 1991, the company offered the first oral anti-rabies vaccine for foxes. A key development came in with the introduction of micro-encapsulation technology, which enabled the creation of the first long-lasting for and , providing sustained efficacy for several days after application. This breakthrough enhanced Virbac's portfolio and underscored its commitment to novel delivery systems in animal health. Concurrently, the company established its first Asian subsidiary in 1992 through a with Maruyasu in , marking an early step toward global reach, and by 1996, it consolidated its French operations under the unified Virbac brand. During the 2000s and , Virbac solidified its position as a global leader through strategic listings, acquisitions, and partnerships that diversified and expanded its portfolio. The company listed on the Paris stock exchange's in 1985, enabling further growth while maintaining family oversight to preserve independence. Key moves included the 2006 acquisition of Agrivet Farm Care in from GlaxoSmithKline, positioning Virbac as India's leading animal health firm, and the purchase of Pfizer's farm animal product rights in , bolstering its parasiticide and offerings. In the , further expansions encompassed a stake in Centrovet in in 2012 for solutions and the 2015 acquisition of Schweitzer Biotech in to enhance swine and production; these efforts helped Virbac extend operations to over 100 countries by the late . In the 2020s, Virbac achieved significant milestones, emerging as the sixth-largest veterinary pharmaceutical group worldwide with a 2024 turnover of €1.397 billion, driven by strong growth in companion animal and food-producing animal segments. In 2020, the company introduced the first intratumoral injectable treatment for canine mastocytomas in and . The company intensified focus on through ongoing investments like the Centrovet integration and zoonotic disease solutions, including its 2015 Corporate Foundation program combating and in . Recent strategic acquisitions, such as Sasaeah in in 2024 for enhanced market leadership and full ownership of Globion in , supported portfolio strengthening amid global challenges. The founding family's influence has ensured operational independence since the founder's death in 1992, when relatives secured majority ownership to guide long-term strategy. In 2025, Virbac laid the foundation for a new vaccine production facility, Bio 5, in Carros, , to meet rising demand for companion animal immunizations.

Products and Services

Companion Animal Portfolio

Virbac's companion animal portfolio encompasses a diverse array of preventive and therapeutic products designed specifically for pets such as , , and ferrets, addressing common health challenges through targeted interventions. These offerings emphasize veterinary-administered solutions that support overall well-being, from routine care to management, with a strong focus on ease of use for pet owners and professionals alike. In dental health, Virbac's C.E.T. Enzymatic Oral Care line stands out as a cornerstone for plaque control and . This includes enzymatic toothpastes formulated with and to mimic natural salivary enzymes, reducing plaque and tartar buildup in s and cats; chews like C.E.T. HEXtra Premium Chews, which promote mechanical cleaning through chewing action; and gels such as C.E.T. AQUADENT FR3SH Dental Solution for water-additive daily maintenance. These products help prevent , a prevalent issue in companion animals, by supporting daily at-home routines alongside cleanings. For parasiticides and heartworm prevention, Virbac provides broad-spectrum options to combat internal and external parasites. Key products include Milpro dewormers, which combine milbemycin oxime and praziquantel in palatable tablets to treat and control roundworms, hookworms, whipworms, and tapeworms in dogs and cats. Flea and tick treatments like EFFIPRO PLUS Topical Solution offer monthly protection against fleas, ticks, and lice. Notably, while Virbac previously held U.S. rights to the Sentinel brand for heartworm and intestinal parasite prevention, these were divested to Merck Animal Health in 2020; current U.S. alternatives include IVERHART MAX Chew, a monthly chewable that prevents heartworm disease and treats hookworms, roundworms, and tapeworms. These solutions are essential for year-round parasite control, particularly in regions with high vector prevalence. Dermatology and ear care products from Virbac target skin infections, allergies, and , common in companion . The lineup features gentle shampoos and cleansers like EPI-SOOTHE , which soothes irritated with colloidal oatmeal and ceramides to restore the barrier, and ALLERDERM Foaming Cleanser for antimicrobial action without drying the coat. For therapeutic needs, antibiotics such as CLINTABS (clindamycin tablets) treat bacterial infections, deep wounds, abscesses, and dental infections in dogs, providing broad-spectrum efficacy against susceptible pathogens. Ear care options include specialized cleansers to manage , supporting resolution of and . Beyond these core areas, Virbac's portfolio extends to behavior aids, mobility supplements, nutrition, vaccines, and in-clinic tools. Behavior management includes ANXITANE Chewable Tablets, containing L-theanine to reduce anxiety and stress in cats and dogs without sedation, and as of 2025, new electric-free pheromone products for managing stress-related behaviors in dogs and cats. Mobility support is addressed by MOVOFLEX Soft Chews, blending glucosamine, chondroitin, and other nutraceuticals to aid joint health and alleviate osteoarthritis symptoms, alongside pain relief options like MOVODYL Chewable Tablets (carprofen) for inflammation and postoperative pain in dogs; in 2025, URSOLYX Soft Chews were introduced for canine muscle support. Nutrition products, such as VETERINARY HPM Spay & Neuter Adult formulas, provide tailored diets to maintain ideal body weight and health post-sterilization; as of 2025, VETERINARY HPM senior formulas were enriched with hyaluronic acid and eggshell membrane for joint support. Vaccines cover critical diseases, including Canigen for canine parvovirus and distemper in dogs, Feligen for feline rhinotracheitis, calicivirus, and panleukopenia in cats, and Canigen Rabies for rabies protection in dogs. In-clinic tools encompass rapid diagnostics like Speed cCRP tests for inflammation monitoring and vector-borne disease panels for quick detection of infections such as Lyme disease, enabling veterinarians to confirm diagnoses and adjust treatments efficiently. These integrated offerings, often backed by Virbac's research innovations, facilitate comprehensive care in veterinary practices.

Livestock and Aquaculture Solutions

Virbac offers a range of solutions for ruminants, including prolonged-release boluses designed for sustained control of internal parasites in and sheep. These boluses, which provide extended protection against gastrointestinal nematodes and liver flukes, help maintain animal by reducing the frequency of treatments and minimizing . For instance, products like those based on formulations target a broad spectrum of parasites, supporting health in extensive systems. Building on early innovations from 1985, these solutions emphasize targeted administration to optimize efficacy while aligning with sustainable parasite management practices. In addition to antiparasitics, Virbac provides vaccines and therapeutics for key livestock species such as pigs, poultry, and cattle, focusing on enhancing and preventing zoonotic diseases. For swine, vaccines like SUIGEN® PRDC offer comprehensive protection against respiratory disease complexes, including porcine reproductive and respiratory , while therapeutics such as MAXFLOR® address bacterial to safeguard quality. In cattle, BOVIGEN™ Platinum vaccines protect against viral respiratory and reproductive pathogens, contributing to reduced antibiotic use and lower zoonotic risks like those from or E. coli transmission. For poultry, Virbac's portfolio includes specialized vaccines acquired through the 2023 acquisition of Globion, targeting common avian diseases to ensure flock health and compliance with standards. These interventions prioritize prevention to mitigate and support biosecure farming environments. Virbac's aquaculture solutions address disease challenges in farmed and , incorporating , , and preventive measures to promote health in intensive production systems. for species like and target bacterial pathogens such as , reducing mortality and the need for therapeutic interventions, while are used judiciously for conditions like furunculosis in cold-water . For , products emphasize to combat virus and other threats. Nutritional supplements, including like BIO MARINE® and mineral additives such as CALGOPHOS®, enhance growth and immunity, while toxin binders like GLYSOMIX POWDER support gut health in high-density ponds. Diagnostic tools, such as rapid immunochromatographic tests, enable on-farm monitoring of pathogens, ensuring early detection and . Integrated into these offerings is a commitment to sustainable practices, such as programs that lower reliance and promote in global operations.

Research and Development

Innovation Strategy

Virbac's innovation strategy is built on a "glocal" model that integrates global research projects with localized adaptations to address diverse veterinary needs across regions. This approach involves initiating projects at R&D centers with a worldwide scope, leveraging multidisciplinary teams to ensure high standards of , , and , while regional units tailor solutions to specific local challenges such as prevalent , farming practices, and regulatory requirements. By distributing R&D efforts across five continents, Virbac enables efficient development of products that are both universally applicable and contextually relevant, fostering a balance between standardized and market-specific responsiveness. The company's key priorities in center on advancing , pharmaceuticals, and diagnostics, with a strong emphasis on preventive care, long-acting formulations, and combating emerging threats like . These efforts draw on expertise in formulation and biological sciences to create high-value medicines that extend treatment durations and promote rational use, thereby reducing risks through prevention-focused alternatives in , pet care, and . This strategic focus aligns with broader goals, ensuring innovations prioritize without extending into human health applications. Virbac's collaborative strategy emphasizes partnerships with veterinarians, academic institutions, research laboratories, and firms to bridge the gap between scientific discovery and practical veterinary solutions. By listening closely to end-users—including veterinarians, farmers, and pet owners—these collaborations inform product development, accelerate access to cutting-edge technologies via licensing, and navigate complex regulatory landscapes over extended 10- to 15-year cycles. To support this, Virbac allocates approximately 9% of its annual revenues to R&D and licensing activities (as of 2025), employing nearly 650 dedicated personnel worldwide (as of end of 2024) to drive ethical, impactful advancements in animal health.

Global R&D Network

Virbac's global research and development (R&D) network encompasses facilities across five continents, with nearly 650 employees dedicated to these efforts worldwide (as of end of 2024). This distributed structure positions the centers near production sites and customer bases, enabling field testing under real-world conditions to develop tailored veterinary solutions. The primary R&D hub operates from Carros and Vauvert, , coordinating overarching global projects, while additional key sites include the ( in , in , in , and in ), ( in , Taiwan in Pingtung, in , in , and in and ), (Penrith and ), and other European locations. These regional facilities focus on localized testing and adaptation, such as addressing specific pathologies or regulatory requirements unique to each area. Under a "glocal" operational model, multidisciplinary teams at these centers advance centralized projects from while incorporating regional expertise for customization—for example, Asian sites in and prioritize innovations to combat emerging diseases in warm-water species. This approach ensures efficient collaboration between global strategy and local implementation, fostering synergies with field teams and external partners like universities and biotech firms. The network's capacity supports comprehensive vaccine development via biological projects at select sites including , , and ; formulation laboratories integrated into all centers for both pharmaceutical and non-pharmaceutical products; and dedicated technical facilities for clinical trials evaluating quality, safety, and efficacy. Overall, this infrastructure underpins Virbac's delivery of solutions across more than 100 countries through localized registration units that monitor compliance and refine products for diverse markets.

Global Operations

International Presence

Virbac maintains a significant presence, with commercial subsidiaries in over 35 countries and product distribution reaching more than 100 countries worldwide. The company's global expansion began in 1982 with the establishment of its first subsidiary in , following the acquisition of local distributor VMG, which marked the start of its deployment across . Today, Virbac operates sales subsidiaries in key markets including the , , , , , , , , , and numerous European nations such as , , the , the , , and . This footprint enables the company to serve veterinarians, farmers, and pet owners through tailored commercial strategies that address regional health challenges. Europe remains Virbac's stronghold and origin market, accounting for approximately 41% of its 2024 consolidated revenue at €570.6 million, driven by strong performance in companion animal products across Western and Central . In , the company has experienced sustained growth, particularly in the U.S., where it focuses on companion animal solutions like and products, contributing about 13% of revenue at €181.6 million in 2024. represents a key expansion area, with revenue of €222.4 million (16% of total) fueled by and solutions in countries like , , and . In and emerging regions, Virbac has deepened its penetration through adaptations such as specialized products for warm-water species like and in , including and , while supporting needs in via vaccines following the 2024 acquisition of Globion. Virbac employs 6,365 people globally as of December 31, 2024, including the integration of recent acquisitions, with a distributed that supports its operations: 2,028 in , 547 in , 1,030 in , 1,122 in , 339 in the Pacific, and 1,299 in , , and the . Dedicated sales teams in these regions collaborate closely with veterinarians to promote product portfolios adapted to local regulations and needs, such as solutions for vector-borne diseases in tropical areas and premium pet nutrition in developed markets like the U.S. This structure facilitates and ensures Virbac's solutions align with diverse geographic and species-specific demands.

Manufacturing and Supply Chain

Virbac maintains a network of manufacturing facilities spanning five continents to produce its range of veterinary , pharmaceuticals, and medical devices, ensuring proximity to key markets and regulatory compliance. The company operates manufacturing sites across 12 countries, including , , , , , , , , , the , , and , allowing for tailored output of specialized products such as injectables and nutritional solutions. In , key sites include the Carros facility, which focuses on production and features a new Bio 5 unit to expand capacity for and dog vaccines, and the plant dedicated to Veterinary HPM therapeutic nutrition. In the , the , facility serves as a central cGMP-compliant hub for , , and of various veterinary products, with finished goods distributed from a consolidated center in Kansas City. The company's prioritizes and adherence to international standards, including Good Manufacturing Practices (GMP), to guarantee product safety and efficacy across its global operations. All Virbac industrial sites are certified under relevant regulatory frameworks, with facilities in holding APVMA-issued GMP licenses for manufacturing veterinary products. Through initiatives like the program, Virbac enhances resilience against disruptions such as geopolitical conflicts by improving processes in , , and logistics, including inbound and outbound transportation, warehousing, and . This integrated approach supports scalable capabilities, accommodating small-batch for companion animal therapeutics alongside large-scale output for and needs. Sustainability is embedded in Virbac's manufacturing and supply chain operations to minimize environmental impact while maintaining efficiency. The company optimizes energy consumption at industrial sites using Best Available Techniques and incorporates in new projects across locations like and ; it also reduces packaging proliferation through eco-design principles and supplier collaborations to enhance recyclability. In , Virbac streamlines freight flows for finished products and upstream materials to lower emissions, as part of broader scope 3 reduction efforts, and greens its vehicle fleet to support responsible logistics. These measures address vulnerabilities identified in site assessments, ensuring operational continuity amid environmental challenges.

Corporate Governance

Leadership and Ownership

Virbac operates as an independent, family-influenced company, having been publicly listed on (ticker: VIRP.PA) since 1985, with the founding Dick family retaining majority control through 50.09% of the and 66.20% of voting rights as of 2024. This structure ensures long-term stability and alignment with the company's original mission in animal health, while allowing access to public markets for growth funding. The family's ongoing influence underscores Virbac's commitment to independence, avoiding external takeovers and prioritizing over short-term gains. The current leadership is headed by Paul Martingell, appointed effective September 1, 2025, following the resignation of Sébastien Huron in September 2024 after 18 years with the company. Martingell, an international expert in health and pharmaceuticals with prior roles at , , and , brings extensive experience in strategic operations and global expansion to guide Virbac's Vision 2030 initiatives. The , comprising seven members including two independents, emphasizes veterinary, pharmaceutical, and business expertise; Chairwoman Marie-Hélène Dick-Madelpuech (family representative) oversees , while Vice-Chairman Pierre Madelpuech and directors like Philippe Capron (former CEO of ) and Olivier Charmeil ( executive) provide balanced oversight drawn from international management backgrounds. Virbac's governance practices are guided by the AFEP-MEDEF Code, with the board providing strategic direction, monitoring ethical compliance, and integrating sustainability into processes. The ensures financial transparency, while the full board reviews progress on (ESG) goals, such as biodiversity conservation and ethical supply chains, without reported major controversies in recent transitions. This framework supports collective and long-term . Key executives complement the CEO in core functions, focusing on innovation and operational resilience. Habib Ramdani serves as and Deputy CEO, managing financial strategy and risk; Bertrand Havrileck leads Corporate R&D, driving in animal therapeutics; André Mathieu directs Global Industrial Operations and Supply Chain, optimizing manufacturing efficiency; and Sophie Favini heads Global Business Operations, coordinating international execution. The eight-member Executive Committee, with balanced gender representation (three women), reports to the CEO and prioritizes agile responses to market needs while upholding the company's independent ethos.

Financial Performance

Virbac reported annual consolidated revenue of €1,397.5 million for 2024, marking a 12.1% increase from €1,246.9 million in 2023, or 13.6% at constant exchange rates. This growth was driven by 7.5% organic expansion and a 6.1% contribution from acquisitions, including Globion and Sasaeah, positioning the company as the sixth-largest veterinary biopharmaceutical group globally. In the first half of 2025, revenue reached €738.3 million, up 5.0% on a reported basis and 5.6% at constant exchange rates and scope, with organic growth of 5.6%. The company's growth trends reflect strong organic performance among peers, particularly in companion animal products, which accounted for the majority of revenue, alongside emerging opportunities in markets. Earlier challenges, such as supply disruptions from the geopolitical conflicts, moderated growth in prior years but have since been mitigated through diversified sourcing and operational resilience. Virbac's expansion strategy, including targeted acquisitions, has enhanced revenue diversification across regions. Key financial metrics underscore improved profitability, with current operating income reaching €231.8 million in 2024, equivalent to a 16.6% margin of revenues—an all-time high and up 1.5 percentage points from 2023 (16.0% excluding acquisition impacts). Net profit attributable to the group rose 20.4% to €145.3 million. Research and development investment remained stable at approximately 8% of revenue, supporting innovation in veterinary solutions. On Euronext Paris (ticker: VIRP), Virbac's shares have shown steady performance, with the company proposing a dividend of €1.45 per share for fiscal 2024, payable in 2025, reflecting a commitment to shareholder returns amid balanced capital allocation. Virbac maintains a competitive edge in and , where it derives significant revenue, while strategic expansions in and drive further diversification and long-term growth. This regional focus, combined with robust , has solidified its market position in the global veterinary pharmaceuticals sector.

References

  1. [1]
    About Virbac
    Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health.
  2. [2]
    Founder - Virbac
    Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health.
  3. [3]
    History - Virbac
    Our founder Pierre-Richard Dick, doctor of veterinary medicine, dies suddenly at the age of 55 while on a Central American sea voyage. Pascal Boissy, then ...
  4. [4]
    Virbac worldwide
    Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health.
  5. [5]
    Our purpose - Virbac
    Advancing the health of animals with those who care for them every day, so we can all live better together: this is our purpose.
  6. [6]
    Our values - Virbac
    Our corporate culture is based on values deeply rooted in our DNA: entrepreneurial spirit, innovation, engagement, customer-driven orientation, attention to ...
  7. [7]
    Encouraging Animal Sentience laws around the world
    Apr 27, 2023 · France was a genuine pioneer in the area of animal protection. Some animals were designated as sentient beings in the 1976 Law on the Protection ...
  8. [8]
    Declaration of Animal Rights - Fondation Droit Animal
    The Universal Declaration for Animal Rights, co-written by LFDA, was solemnly proclaimed on 15 October 1978 at UNESCO house in Paris.
  9. [9]
    [PDF] ANNUAL REPORT 2017 - AnnualReports.com
    Apr 30, 2017 · The Virbac share is listed on the Paris stock exchange in section B of the Euronext. Virbac is a public limited company under French law ...
  10. [10]
    About Us - Virbac
    It was founded over 50 years ago, in 1968, by a French veterinarian Pierre-Richard Dick. He wanted the company to have a strong focus on vaccines and ...Missing: history early 1980s
  11. [11]
    2024 annual results - Virbac
    Mar 13, 2025 · At the end of December 2024, our annual revenue reached €1,397.5 million compared to €1,246,9 million, representing an overall increase of +12.1 ...
  12. [12]
    Leading Animal Health Organizations Chart a Path Toward a ...
    Sep 4, 2025 · This performance secured our position as the 6th largest veterinary drug manufacturer worldwide, reflecting a 7.5% growth at constant exchange ...Missing: group | Show results with:group
  13. [13]
    Virbac to take a leading position in Japan through the acquisition of ...
    Mar 6, 2024 · Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah.Missing: milestones | Show results with:milestones
  14. [14]
    Virbac completes acquisition of Indian company Globion
    On June 21, 2024, Virbac finalized the acquisition of the minority stake in Globion, thereby increasing its participation to 100%.
  15. [15]
    https://www.virbac.com/home/news-media/news/pagecontent/toutes-les-actualites-presse-vir/carros-new-factory-meet-the-growing-demand-for-cat-dog-vaccines.html
  16. [16]
    Product Selector - Virbac
    Virbac is an animal health pharmaceutical company that specializes in dental, medicine, and supplements for dogs, cats, and ferrets in the United States.Dental · Parasiticides · Nutrition · Pet NutritionMissing: companion dermatology
  17. [17]
    Dental - Virbac
    Virbac is an animal health pharmaceutical company that specializes in dental, medicine, and supplements for dogs, cats, and ferrets in the United States.C.E.T.® Enzymatic Oral... · C.E.T.® Enzymatic Toothpastes · CET Hextra ChewsMissing: dermatology | Show results with:dermatology
  18. [18]
    https://us.virbac.com/products/parasiticides/effipro-plus-cats
  19. [19]
    Milpro ® - Deworming medication for dogs and cats - Virbac India
    Milpro® - Deworming medication for dogs and cats · Broad-spectrum efficacy against intestinal worms such as tapeworms (Cestodes) and roundworms (Nematodes) ...
  20. [20]
    Virbac completes divestment of U.S. Rights to SENTINEL​® brands ...
    Jul 2, 2020 · Virbac, today announced the successful completion of its divestment of the U.S. rights to its parasiticides for dogs: SENTINEL® FLAVOR TABS® ...<|control11|><|separator|>
  21. [21]
    CLINTABS® (clindamycin hydrochloride) Tablets - Virbac
    14-day returnsCLINTABS treats skin, deep wounds, dental infections, and osteomyelitis in dogs caused by susceptible microorganisms.
  22. [22]
    VETERINARY HPM® Dog Food - Virbac US
    VETERINARY HPM Dog Food for spayed and neutered dogs can be purchased at your veterinarian's clinic or online through iVet for delivery straight to your home.
  23. [23]
    Vaccines - Virbac
    Through our broad range of safe and reliable vaccines, we help improve the quality of life for farm and companion animals and preserve biodiversity and ...
  24. [24]
    Virbac Diagnostics
    Our tests are focused on companion animals and farm animals diseases, and are performed in-field or in-clinic by the veterinarian. Our aim is to assist ...
  25. [25]
    Virbamec LA | Injectable antiparasitic remedy for cattle, sheep, pigs ...
    Long-acting injectable antiparasitic remedy for cattle, sheep, pigs and ostriches. ... Do not use intravenously. Use of a 2,0 cm 16 gauge needle is recommended.
  26. [26]
    Virbamec L | Liver Fluke Control in Cattle and Sheep | Virbac
    Virbamec L is a comprehensive injectable for Internal and External parasites, as well as Liver fluke control in cattle and sheep.
  27. [27]
    Cattle Vaccines - Virbac
    BOVIGEN™ Platinum Vaccines from Virbac deliver quality protection against viral respiratory and both viral and bacterial reproductive diseases in the vaccine ...Missing: companion | Show results with:companion
  28. [28]
    SUIGEN® PRDC: (6-in-1) ALL-in-ONE Vaccine for Piglets and Sows
    SUIGEN PRDC is a multivalent vaccine that effectively prevents complex respiratory diseases and diseases commonly associated with blue ear disease.
  29. [29]
    Swine
    MAXFLOR® Florfenicol - Based Products for Treatment of Respiratory Diseases. Read more. PORCISTART™: A Gel Protein Supplementation For Growing Piglets. Read ...
  30. [30]
    Cattle - Virbac
    Vaccination strengthens the animal's immune functions for rapid and lasting protection. ... livestock and to the fight against zoonoses. MICRONUTRITION OVER ...Missing: therapeutics poultry safety
  31. [31]
    Aquaculture - Virbac
    Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health.
  32. [32]
    Providing sustainable solutions to the global aquaculture boom
    Mar 24, 2022 · Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health.
  33. [33]
    Helpful tips on Aquaculture and farming - Virbac India
    Shrimp Hatchery · AGRIMIN® Powder – Minerals and Amino Acid Supplement For Aquaculture Use · BIO MARINE® - Probiotic for aquaculture use · CALGOPHOS® nutritional ...Shrimp Hatchery · Probiotics · Every Aqua advices · What Are Probiotics and Their...
  34. [34]
    Fish Antibiotics |GLYSOMIX POWDER - Virbac India
    Glysomix TM Powder helps to bind harmful toxins in shrimp gut and thus helps to maintain survivability and growth.
  35. [35]
    Diagnostic - Virbac
    Diagnosis is key to companion and farm animal care and disease control in livestock: it enables the detection or confirmation of the disease, the adjustment ...
  36. [36]
    Supporting sustainable farming - Virbac
    At Virbac, we are actively contributing to the adoption of these new practices by proposing a more sustainable approach to rearing techniques.
  37. [37]
    An international R&D network - Virbac
    Virbac's innovation is organized to facilitate the development of projects with a global vocation from the outset. Our Virbac R&D centers are located on five ...Missing: strategy priorities
  38. [38]
    Our innovation model - Virbac
    Our innovation model, which spans biologicals, pharmaceuticals, diagnostics, petfood and pet care, is based on four pillars.Missing: strategy | Show results with:strategy
  39. [39]
    Where is Virbac Located? HQ & Global Offices (2025)
    As the birthplace of Virbac, the Carros headquarters is historically and strategically crucial. It symbolizes the company's origins and continues to drive its ...
  40. [40]
    Virbac Subsidiaries
    Virbac subsidiaries ; Germany · Spain · Netherlands · Italy · United Kingdom · Switzerland · Belgium · Austria · Portugal · Greece · Denmark · Poland · Hungary ...Missing: presence operations
  41. [41]
    Virbac Corporate
    Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical company exclusively dedicated to animal health.About Virbac · History · Investors · Virbac worldwide
  42. [42]
    None
    Below is a merged summary of the Virbac 2024 Annual Report, consolidating all information from the provided segments into a comprehensive response. To handle the dense and varied data efficiently, I’ve organized key details into tables where appropriate (e.g., employee numbers, regional revenue breakdowns, and geographic footprint). Narrative sections are used for qualitative information like market adaptations and key markets. All unique data points are retained, and discrepancies (e.g., varying employee numbers) are included with their respective sources for clarity.
  43. [43]
    https://corporate.virbac.com/home/news-media/financial-public-releases/pagecontent/tous-les-communiques-financiers/resultats-semestriels-2025.html
  44. [44]
    Discover Virbac
    We moved our North American headquarters from an Meacham Blvd to the Solana complex, providing much quicker access to the airport, restaurants and other ...
  45. [45]
    A new factory to meet the growing demand for cat and dog vaccines
    We are going to increase our vaccine production capacity with the construction of a new industrial site, Bio 5, in Carros (Alpes-Maritimes).Missing: headquarters move
  46. [46]
    Virbac to integrate all production under one roof with new facility
    Oct 14, 2022 · Virbac announced plans for a new production site located in Nîmes. The new facility will integrate all production processes for the company's Veterinary HPM ...
  47. [47]
    Virbac Distribution Center - St. Louis, Missouri
    Our main manufacturing facility is located on 37 acres in Bridgeton, Missouri, a suburb of St. Louis. The 193,000 sq. ft. main building has seen continuous ...
  48. [48]
    Virbac North American Headquarters - Westlake, Texas
    Virbac's North American headquarters are located in the Solana business district of Westlake, Texas. Under the direction of Giovanni Abruzzini, CEO & President.Missing: R&D | Show results with:R&D
  49. [49]
    [PDF] ANNUAL REPORT 2022 - AnnualReports.com
    100% of Virbac industrial sites are certified. 100% of employees are trained ... The list of consolidated companies is provided in note A40. All ...<|separator|>
  50. [50]
    About Virbac Australia
    1982. filiale-allemagne.png The opening of our first subsidiary in Germany, following acquisition of local distributor VMG, marks the beginning of our ...
  51. [51]
    Odyssey program: towards the industry of tomorrow - Virbac
    Nearly 800 employees will benefit from these improvements in various areas such as quality control, production, quality assurance, supply chain, purchasing, ...Missing: facilities | Show results with:facilities<|control11|><|separator|>
  52. [52]
    Virbac SubTropolis - Kansas City, Missouri
    These activities include inbound and outbound transportation management, warehousing, materials handling, order fulfillment, logistics network design, inventory ...Missing: chain | Show results with:chain
  53. [53]
    Protecting the environment - Virbac
    Our Group has conducted a preliminary analysis of the exposure and vulnerability of its activities to physical climate risks.Missing: GMP | Show results with:GMP
  54. [54]
    2025 half-year results - Virbac
    Sep 12, 2025 · The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.Missing: milestones expansion
  55. [55]
    Virbac (EPA:VIRP) Dividend History, Dates & Yield - Stock Analysis
    Virbac has an annual dividend of €1.45 per share, with a yield of 0.43%. The dividend is paid once per year and the last ex-dividend date was Jun 24, 2025.